Celltrion signs $316 million biosimilars supply deal

Celltrion's Remsima, a biosimilar copy of Janssen Biotech's Remicade that treats autoimmune diseases [CELLTRION]

Celltrion signed a 423.6 billion won ($316 million) supply deal with Celltrion Healthcare, its distributor, the biopharmaceutical company said Monday.

The deal is Celltrion’s largest quarterly supply contract, according to the company. With the signing of the deal, Celltrion will provide Celltrion Healthcare with its biosimilar products, including its autoimmune disease treatment biosimilar Remsima, blood cancer treatment Truxima and stomach cancer treatment Herzuma.

Celltrion Healthcare is a marketing company that handles the overseas distribution of products developed by Celltrion, the biosimilar company.

Celltrion Healthcare said Monday that it won tenders in European countries including France and Italy for its biosimilar products. Celltrion’s blood treatment Truxima will be supplied exclusively to France’s AP-HP, an alliance of teaching hospitals in Paris and the Île-de-France region.

BY SHIN HA-NEE [shin.hanee@joongang.co.kr]